Novartis increases sales of Genmab-developed sclerosis drug

On Wednesday, Novartis presented its full-year financial report, including sales figures for sclerosis drug Kesimpta, which was originally developed in Genmab’s labs.

Photo: CHARLES PLATIAU/Reuters / X00217

Genmab’s Swiss partner, Novartis, continues to push sales for sclerosis drug Kesimpta.

The treatment reached a revenue of USD 147m in the fourth quarter of the year, and for the full-year, sales amounted to USD 372m, according to Novartis’s financial report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs